Tesla and Warner Bros. scored a partial legal victory as a federal judge dismissed several claims in a lawsuit filed by Alcon Entertainment, a production company behind the 2017 sci-fi movie Blade ...

In patients with posterior capsule rupture, 60% of cases occurred during the stage of phacoemulsification. The timing of rupture is likely affected by the presence of anterior capsule tears.

Editor’s note: This is a developing news story. Please check back soon for updates. Alcon has acquired a majority interest in Aurion Biotech, according to a press release. Aurion will operate as ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.

During a surgical process, doctors need many handpiece consumables ... and technical support for these machines. Alcon has the top market position in phacoemulsification (70% in the US and 50% ...

Eye care company Alcon Inc., which has a major presence in North Texas, plans to buy Lensar Inc. in a deal valued up to $430 million. Orlando-based Lensar (Nasdaq: LNSR) is a laser cataract ...

The leading eye-care company Alcon on Wednesday said it has acquired a majority stake in Aurion Biotech, capping months of legal wrangling over the future of the cell therapy developer. As part of the ...

Alcon's acquisition of Aurion Biotech enhances its cell therapy capabilities for eye diseases, with Aurion operating independently under Alcon's support. Aurion's AURN001, an allogeneic cell therapy ...

Swiss ophthalmic drug company Alcon (SIX/NYSE: ALC) today announced it has acquired a majority interest in Aurion Biotech, a privately-held US clinical-stage company developing advanced cell therapies ...

GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in ...

Nkarta is laying off a third of its workforce, and more than half its executive team, in a bid to survive long enough to see if an experimental cell therapy it’s developing will show promise against ...